Tumor mutation burden in the prognosis and response of lung cancer patients to immune-checkpoint inhibition therapies

Immune checkpoint inhibition (ICI) therapies have reshaped the therapeutic landscape in lung cancer management, providing first-time improvements in patient response, prognosis, and overall survival. Despite their clinical effectiveness, variability in treatment responsiveness, as well as drug resis...

Descripción completa

Detalles Bibliográficos
Autores principales: Vryza, Paraskevi, Fischer, Timo, Mistakidi, Elena, Zaravinos, Apostolos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2023
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10542015/
https://www.ncbi.nlm.nih.gov/pubmed/37776617
http://dx.doi.org/10.1016/j.tranon.2023.101788

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10542015/
https://www.ncbi.nlm.nih.gov/pubmed/37776617
http://dx.doi.org/10.1016/j.tranon.2023.101788

Ejemplares similares